Literature DB >> 20952739

Isochromosome 5p, a novel recurrent abnormality in breast cancer: is it a common abnormality in cancer?

Anna D Panani1.   

Abstract

BACKGROUND: The detection of recurring genetic changes in breast cancer can be extremely difficult. The tumors display very complex structural chromosomal rearrangements the origin of which are often very difficult to establish. The identification of recurrent chromosomal changes is a useful strategy for understanding tumorigenesis and specific chromosomal associations. Isochromosome i(5p) is a frequent finding in several types of cancer but it has been rarely described in breast cancer. The aim of the present study was to investigate the presence of i(5p) in primary breast tumors.
MATERIALS AND METHODS: Sixteen cases of breast cancer were cytogenetically studied by direct culture of cancerous cells and G-banding technique. We focused on structural aberrations of chromosome 5 in order to identify the presence of i(5p) in breast cancer.
RESULTS: All the cases presented complex chromosomal changes with hyperploidization and various unidentified marker chromosomes being the prominent finding. Among 16 cases studied 6 cases presented an i(5p). No other structural abnormalities of chromosome 5 could be identified.
CONCLUSION: The presence of i(5p) in breast tumors suggests that this chromosomal abnormality plays an important role in the development of breast cancer. Isochromosome 5p needs to be further molecularly analyzed as a candidate region for the isolation of genes related to carcinogenesis. Moreover, the fact that i(5p) has been described in several different tumor types suggests that there are no fundamental tissue-specific differences in the genetic mechanisms leading to tumorigenesis.

Entities:  

Mesh:

Year:  2010        PMID: 20952739

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  2 in total

1.  TAaCGH Suite for Detecting Cancer-Specific Copy Number Changes Using Topological Signatures.

Authors:  Jai Aslam; Sergio Ardanza-Trevijano; Jingwei Xiong; Javier Arsuaga; Radmila Sazdanovic
Journal:  Entropy (Basel)       Date:  2022-06-29       Impact factor: 2.738

2.  Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAFV600E.

Authors:  Zeus A Antonello; Nancy Hsu; Manoj Bhasin; Giovanni Roti; Mukta Joshi; Paul Van Hummelen; Emily Ye; Agnes S Lo; S Ananth Karumanchi; Christine R Bryke; Carmelo Nucera
Journal:  Oncotarget       Date:  2017-09-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.